We will be comparing the differences between Verastem Inc. (NASDAQ:VSTM) and OncoSec Medical Incorporated (NASDAQ:ONCS) as far as risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem Inc.	26.72M	6.17	72.43M	-1.44	0.00
OncoSec Medical Incorporated	N/A	0.00	38.39M	-0.88	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Verastem Inc. and OncoSec Medical Incorporated.

Profitability

Table 2 shows Verastem Inc. and OncoSec Medical Incorporated’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Verastem Inc.	-271.07%	-95.9%	-61.7%
OncoSec Medical Incorporated	0.00%	-165.1%	-134.2%

Volatility and Risk

Verastem Inc. has a 3.05 beta, while its volatility is 205.00%, thus making it more volatile than Standard & Poor’s 500. OncoSec Medical Incorporated on the other hand, has 2.04 beta which makes it 104.00% more volatile compared to Standard & Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Verastem Inc. are 3 and 3 respectively. Its competitor OncoSec Medical Incorporated’s Current Ratio is 5.4 and its Quick Ratio is 5.4. OncoSec Medical Incorporated can pay off short and long-term obligations better than Verastem Inc.

Analyst Ratings

Ratings and Recommendations for Verastem Inc. and OncoSec Medical Incorporated can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Verastem Inc.	0	0	4	3.00
OncoSec Medical Incorporated	0	1	0	2.00

Verastem Inc. has a 292.38% upside potential and a consensus price target of $8.75.

Insider and Institutional Ownership

The shares of both Verastem Inc. and OncoSec Medical Incorporated are owned by institutional investors at 61.5% and 6.4% respectively. Verastem Inc.’s share held by insiders are 0.6%. Insiders Comparatively, held 17.4% of OncoSec Medical Incorporated shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Verastem Inc.	-6.71%	-6.71%	-39.88%	-68.31%	0.33%	-8.93%
OncoSec Medical Incorporated	-3.71%	-38.64%	-37.87%	-63.01%	-70.17%	-15.62%

For the past year Verastem Inc. has stronger performance than OncoSec Medical Incorporated

Summary

Verastem Inc. beats on 6 of the 10 factors OncoSec Medical Incorporated.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The companyÂ’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The companyÂ’s duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. The company also has completed two Phase II studies for products, such as OMS-I100 in metastatic melanoma and OMS-I110 in merkel cell carcinoma. It has a clinical collaboration with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte; and a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the combination of OncoSec's ImmuoPulse IL-12 with MerckÂ’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase II clinical trial referred to as PISCES. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.